• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ABATACEPT Drug Record

  • Summary
  • Interactions
  • Claims
  • ABATACEPT chembl:CHEMBL1201823 ApprovedImmunotherapy

    Alternate Names:

    RG-2077
    ORENCIA
    ABATACEPT (GENETICAL RECOMBINATION)
    CTLA4-IGG4M
    BMS-188667
    ABATACEPT
    ORENCIA CLICKJECT
    RG-1046
    CTLA4IGG4M
    CTLA4-IG
    CTLA4IG
    drugbank:01281
    chemidplus:332348-12-6
    chembl:CHEMBL1201823
    rxcui:614391

    Drug Info:

    FDA Approval not approved
    Drug Class protein
    Drug Indications immunosuppressant
    Year of Approval 2005
    Drug Class antirheumatic agents
    FDA Approval approved
    Drug Class fusion protein
    Drug Indications antiinflammatory agent,DMARD
    (3 More Sources)

    Publications:

    Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.
    Nogid et al., 2006, Role of abatacept in the management of rheumatoid arthritis., Clin Ther
    Kremer, 2005, Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis., J Clin Rheumatol
    Scheinfeld, 2006, Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists., J Dermatolog Treat
    Vincenti et al., 2007, T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation., Annu. Rev. Med.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Reynolds et al., 2007, Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis., Pharmacotherapy
    Weyand et al., 2006, T-cell-targeted therapies in rheumatoid arthritis., Nat Clin Pract Rheumatol
    Hervey et al., 2006, Abatacept., BioDrugs
    Maxwell et al., 2010, Abatacept for rheumatoid arthritis: a Cochrane systematic review., J. Rheumatol.
    Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.
  • ABATACEPT   CD80

    Interaction Score: 38.64

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CTLA4
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    10604996 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND TTD

  • ABATACEPT   CD86

    Interaction Score: 38.28

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction T-lymphocyte activation antigen CD86 inhibitor
    Trial Name Orencia

    PMIDs:
    17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • ABATACEPT   CTLA4

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9758890


    Sources:
    NCI

  • TEND: ABATACEPT

    • Version: 01-August-2011

    Alternate Names:
    ABATACEPT Primary Drug Name

    Drug Info:
    Drug Class antirheumatic agents
    Year of Approval 2005

    Publications:

  • TdgClinicalTrial: RG-2077

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications immunosuppressant
    Drug Class protein
    FDA Approval not approved

    Publications:

  • TdgClinicalTrial: ABATACEPT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class fusion protein
    FDA Approval approved

    Publications:

  • NCI: CTLA4-IG

    • Version: 14-September-2017

    Alternate Names:
    C28898 NCI drug code

    Drug Info:

    Publications:
    Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.
    Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.

  • TTD: Abatacept

    • Version: 2020.06.01

    Alternate Names:
    D0EW4L TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201823

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201823

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21